Latest Breaking News On - Telix pharmaceuticals limited - Page 2 : comparemela.com

TLX591 is an investigational anti-PSMA[1] radio-antibody-drug conjugate rADC therapy being developed for the treatment of mCRPC differentiated by a short two-week dosing regimen Reported median radiographic progression-free survival rPFS is 88 months Builds on prior data from the ProstACT SELECT[2] trial demonstrating favourable safety profile and biodistribution[3] MELBOURNE Australia May 31 2024 PRNewswire Telix Pharmaceuticals Limited ASX TLX Telix the Company today announces additional positive datafrom the ProstACT SELECT trial SELECT of TLX591 177Lu rosopatamab tetraxetan a lutetium-labelled rADC therapy for the treatment of adult patients with PSMA-positive metastatic castrate-resistant prostate cancer mCRPC SELECT is a radiogenomics study intended to evaluate lesion concordance between 68Ga gallium-based PSMA-PET[4] imaging and TLX591 dosimetry for the purpose of validating PET imaging for patient selection for rADC therapy The Company has previously reported final safety data

United statesKyahn williamsonDavidn cadeNat lenzoHealth canadaTelix pharmaceuticals limitedAustralian securities exchangeTelix pharmaceuticals limited disclosure committeeCorporate communicationsDrug administrationTelix pharmaceuticalsNuclear oncologistAustralian therapeutic goods administrationGeneral internal medicine physicianGroup chief medical officerNuc med